Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium

Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) targeting Nectin-4, has been available as standard care for metastatic urothelial carcinoma (mUC) patients who have progressed after platinum-based chemotherapy and checkpoint inhibitors (CPIs). However, the association between body mass inde...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical oncology 2025-01
Hauptverfasser:	Uchimoto, Taizo, Iwatsuki, Kengo, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Saruta, Masanobu, Hashimoto, Mamoru, Minami, Takafumi, Yamamoto, Yutaka, Yamazaki, Shogo, Takai, Tomoaki, Sakamoto, Moritoshi, Nakajima, Yuki, Nishimura, Kazuki, Maenosono, Ryoichi, Tsujino, Takuya, Nakamura, Ko, Fukushima, Tatsuo, Nishio, Kyosuke, Yoshikawa, Yuki, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Fujita, Kazutoshi, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Azuma, Haruhito
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) targeting Nectin-4, has been available as standard care for metastatic urothelial carcinoma (mUC) patients who have progressed after platinum-based chemotherapy and checkpoint inhibitors (CPIs). However, the association between body mass index (BMI) and clinical outcomes for EV remains unknown. We analyzed the records of 123 mUC patients who received EV. The cohort was divided into low BMI (
ISSN:	1341-9625 1437-7772 1437-7772
DOI:	10.1007/s10147-025-02709-1